What question did this study set out to answer?

This study aims to compare the glycemic outcomes of Dexcom and FreeStyle Libre continuous glucose monitoring systems in type 1 diabetes patients using automated insulin delivery systems.

June 7, 2026

1871-P: Retrospective Analysis and Comparison of Dexcom and Libre Continuous Glucose Monitoring Systems in Automated Insulin Delivery Users: The Delica₀1 Study

Key Points

This study aims to compare the glycemic outcomes of Dexcom and FreeStyle Libre continuous glucose monitoring systems in type 1 diabetes patients using automated insulin delivery systems.
Retrospective analysis of adult individuals with T1D using either Dexcom G6/G7 or FreeStyle Libre 2/3 CGMs along with CamAPS FX.
Included users had valid continuous CGM data for ≥14 days.
Primary outcome focused on time in range (70-180 mg/dL) and secondary outcomes included time below range and time above range.
52 individuals were analyzed: 36 using Dexcom and 16 using Libre.
Dexcom users showed a median HbA1c of 49.4 mmol/mol and Libre users had a median HbA1c of 52.4 mmol/mol during a mean observation of 89 days.
Higher time in range was noted for Dexcom users compared to Libre users, although caution is advised due to small sample size.

Abstract

Introduction and Objective: CGM systems are essential in managing type 1 diabetes (T1D), especially when used alongside automated insulin delivery. However, real-world data comparing different CGM systems, integrated in AID therapy, remain limited. This retrospective study compared glycemic outcomes, specifically time in range, between users of Dexcom G6/G7 and FreeStyle Libre 2/3 CGM systems combined with the CamAPS FX-YpsoPump AID system. Methods: Adult individuals with T1D using Dexcom G6/G7 or FreeStyle Libre 2/3 CGMs with the CamAPS FX system were included. Data of AID users was taken in if they had continuous ≥14 days of valid CGM data. The primary outcome was time in range (70-180 mg/dL), secondary outcomes were TBR and TAR. Results: Data from 52 individuals were analyzed (Dexcom: n=36; Libre: n=16). During a mean use of 89 ± 0.2 days, median HbA1c was 49.4 ± 9.0 mmol/mol for Dexcom users and 52.4 ± 7.6 mmol/mol for Libre users. Table 1 compares the TIR, TBR, and TAR between Dexcom and Libre users. Conclusion: Dexcom G6/G7 (n=35/1) use within CamAPS FX AID therapy was associated with numerically higher TIR compared with FreeStyle Libre 2/3 (n=1/15). These findings should be interpreted with caution given the small sample size, short observation period and lack of statistical power. Larger prospective studies are needed to confirm potential differences between CGM systems in AID therapy. Disclosure S. Basta: None. P.M. Baumann: None. M. Cigler: None. F. Aberer: Advisory Panel; Ended; Bayer AG, Eli Lilly and Company. D.A. Hochfellner: Speaker's Bureau; Ended; Sanofi. Stock/Shareholder; Ended; Novo Nordisk A/S. D.A. Kraus: None. J.K. Mader: Research Support; Current; A. Menarini Diagnostics. Advisory Panel; Current; Abbott Diabetes. Speaker's Bureau; Current; Abbott Diabetes. Advisory Panel; Current; Becton, Dickinson and Company. Speaker's Bureau; Current; Becton, Dickinson and Company. Advisory Panel; Current; Insulet Corporation, Eli Lilly and Company. Speaker's Bureau; Current; Eli Lilly and Company. Advisory Panel; Current; Sanofi. Speaker's Bureau; Current; Sanofi. Advisory Panel; Current; Novo Nordisk A/S. Speaker's Bureau; Current; Novo Nordisk A/S. Advisory Panel; Current; Roche Diagnostics. Speaker's Bureau; Current; Roche Diagnostics. Advisory Panel; Current; Medtronic, Tandem Diabetes Care, Inc., Omnipod. Stock/Shareholder; Current; decide Clinical Software GmbH. Advisory Panel; Current; Dexcom, Inc. Speaker's Bureau; Current; Dexcom, Inc., Sinocare, Buzud. Advisory Panel; Current; Biomea Fusion, Pharmasens. Stock/Shareholder; Current; elyte Diagnostics. Other - CMO (unpaid); Current; elyte Diagnostics. Speaker's Bureau; Current; A. Menarini Diagnostics. Board Member; Current; OMNIA by AI APS. Advisory Panel; Current; Triple Jump.

Mark Helpful

Bookmark

Relay